The patients signed the written informed consent
The patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III)
The breast tumor's positive ER/PR rate is <1%, and positive ER-beta1 rate is =10% by IHC.
The patients have no history of neoadjuvant hormone therapy.
The patients have normal cardiac functions by echocardiography.
The patients' ECOG scores are =0-2.
Female patient who is = 18yrs, and = 65yrs.
The patients are non-pregnant, and disposed to practice contraception during the whole trial.
The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer.
The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin) after surgery according to the 2013 NCCN guideline.
The results of patients' blood tests are as follows:

NCT02062489_inc_T2
Qualifier
operable
NCT02062489_inc_T3
Qualifier
unilateral
NCT02062489_inc_T4
Qualifier
invasive
NCT02062489_inc_T5
Condition
breast cancers
NCT02062489_inc_T6
Condition
distant metastasis
NCT02062489_inc_T7
Negation
without
NCT02062489_inc_T8
Measurement
stage
NCT02062489_inc_T9
Value
I, II, and III
NCT02062489_inc_T10
Scope
without distant metastasis
NCT02062489_inc_T11
Condition
breast tumor
NCT02062489_inc_T12
Measurement
positive ER/PR rate
NCT02062489_inc_T13
Value
<1%
NCT02062489_inc_T14
Measurement
positive ER-beta1 rate
NCT02062489_inc_T15
Value
=10%
NCT02062489_inc_T16
Procedure
IHC
NCT02062489_inc_T17
Scope
positive ER/PR rate is <1%, and positive ER-beta1 rate is =10%
NCT02062489_inc_T18
Procedure
neoadjuvant hormone therapy
NCT02062489_inc_T19
Negation
no history
NCT02062489_inc_T21
Condition
normal cardiac functions
NCT02062489_inc_T20
Procedure
echocardiography
NCT02062489_inc_T22
Measurement
ECOG scores
NCT02062489_inc_T23
Value
=0-2
NCT02062489_inc_T24
Person
Female
NCT02062489_inc_T25
Value
= 18yrs
NCT02062489_inc_T26
Value
= 65yrs
NCT02062489_inc_T27
Scope
= 18yrs, and = 65yrs
NCT02062489_inc_T29
Procedure
neoadjuvant chemotherapy
NCT02062489_inc_T30
Procedure
surgery
NCT02062489_inc_T31
Procedure
radical mastectomy
NCT02062489_inc_T32
Qualifier
directly modified
NCT02062489_inc_T33
Scope
neoadjuvant chemotherapy plus surgery
NCT02062489_inc_T34
Procedure
breast-conserving surgery
NCT02062489_inc_T35
Procedure
sentinel lymph node biopsy
NCT02062489_inc_T36
Procedure
axillary lymph node dissection
NCT02062489_inc_T37
Temporal
after diagnosis of breast cancer
NCT02062489_inc_T38
Reference_point
diagnosis of breast cancer
NCT02062489_inc_T39
Scope
neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection)
NCT02062489_inc_T40
Procedure
chemotherapy
NCT02062489_inc_T41
Procedure
radiation therapy
NCT02062489_inc_T42
Procedure
targeted therapy
NCT02062489_inc_T43
Drug
herceptin
NCT02062489_inc_T44
Reference_point
surgery
NCT02062489_inc_T45
Temporal
after surgery
NCT02062489_inc_T46
Procedure
surgery
NCT02062489_inc_T47
Qualifier
2013 NCCN guideline
NCT02062489_inc_T48
Scope
chemotherapy, radiation therapy or targeted therapy(herceptin)